Bryan Bergman
Concepts (464)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insulin Resistance | 55 | 2026 | 1244 | 8.500 |
Why?
| | Muscle, Skeletal | 43 | 2026 | 1789 | 5.950 |
Why?
| | Adipose Tissue | 19 | 2026 | 645 | 4.060 |
Why?
| | Triglycerides | 17 | 2024 | 520 | 2.960 |
Why?
| | Exercise | 17 | 2026 | 2198 | 2.810 |
Why?
| | Obesity | 37 | 2026 | 3116 | 2.780 |
Why?
| | Sphingolipids | 8 | 2024 | 83 | 2.650 |
Why?
| | Diabetes Mellitus, Type 2 | 23 | 2024 | 2588 | 2.640 |
Why?
| | Diglycerides | 9 | 2026 | 61 | 2.270 |
Why?
| | Insulin | 28 | 2025 | 2512 | 2.170 |
Why?
| | Weight Loss | 6 | 2026 | 858 | 2.060 |
Why?
| | Lipid Metabolism | 14 | 2026 | 529 | 1.680 |
Why?
| | Liver | 14 | 2026 | 1896 | 1.660 |
Why?
| | Physical Endurance | 13 | 2025 | 279 | 1.580 |
Why?
| | Fasting | 7 | 2025 | 279 | 1.570 |
Why?
| | Blood Glucose | 29 | 2025 | 2341 | 1.560 |
Why?
| | Ceramides | 8 | 2025 | 117 | 1.390 |
Why?
| | Glucose Clamp Technique | 22 | 2025 | 199 | 1.380 |
Why?
| | Lipids | 5 | 2024 | 707 | 1.380 |
Why?
| | Phosphatidylcholines | 2 | 2024 | 130 | 1.250 |
Why?
| | Sarcolemma | 3 | 2024 | 35 | 1.150 |
Why?
| | Rest | 6 | 2017 | 124 | 1.110 |
Why?
| | Paracrine Communication | 2 | 2025 | 67 | 1.040 |
Why?
| | Muscle Fibers, Skeletal | 5 | 2024 | 212 | 1.030 |
Why?
| | Lipogenesis | 4 | 2017 | 62 | 1.020 |
Why?
| | Fatty Acids, Nonesterified | 10 | 2022 | 154 | 0.960 |
Why?
| | Prediabetic State | 5 | 2016 | 249 | 0.880 |
Why?
| | Intra-Abdominal Fat | 4 | 2022 | 101 | 0.880 |
Why?
| | Glucose | 10 | 2025 | 1048 | 0.870 |
Why?
| | Receptors, Gastrointestinal Hormone | 1 | 2023 | 7 | 0.810 |
Why?
| | Glucose Tolerance Test | 11 | 2021 | 360 | 0.800 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2023 | 149 | 0.800 |
Why?
| | Pancreas | 1 | 2025 | 341 | 0.740 |
Why?
| | Dietary Fats | 6 | 2020 | 308 | 0.740 |
Why?
| | Subcutaneous Fat | 4 | 2025 | 79 | 0.730 |
Why?
| | Adult | 48 | 2026 | 40777 | 0.730 |
Why?
| | Carnitine | 3 | 2024 | 91 | 0.720 |
Why?
| | Tandem Mass Spectrometry | 4 | 2024 | 572 | 0.720 |
Why?
| | Male | 71 | 2026 | 72842 | 0.690 |
Why?
| | Humans | 93 | 2026 | 145474 | 0.680 |
Why?
| | Diabetes Mellitus, Type 1 | 18 | 2019 | 3922 | 0.660 |
Why?
| | Female | 68 | 2026 | 78844 | 0.640 |
Why?
| | Athletes | 7 | 2024 | 424 | 0.630 |
Why?
| | Fatty Liver | 4 | 2026 | 253 | 0.570 |
Why?
| | Energy Metabolism | 5 | 2025 | 935 | 0.570 |
Why?
| | Transcription, Genetic | 1 | 2025 | 1454 | 0.560 |
Why?
| | Middle Aged | 32 | 2026 | 36215 | 0.550 |
Why?
| | Glucose Intolerance | 4 | 2014 | 142 | 0.520 |
Why?
| | Lactic Acid | 7 | 2009 | 295 | 0.510 |
Why?
| | Oxidation-Reduction | 8 | 2024 | 1067 | 0.510 |
Why?
| | Adipocytes | 2 | 2023 | 223 | 0.500 |
Why?
| | Phosphatidylethanolamines | 2 | 2017 | 76 | 0.490 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2019 | 592 | 0.490 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1399 | 0.480 |
Why?
| | Choristoma | 1 | 2015 | 20 | 0.460 |
Why?
| | Body Composition | 10 | 2025 | 693 | 0.450 |
Why?
| | Mitochondria, Muscle | 5 | 2021 | 120 | 0.430 |
Why?
| | Diet, Western | 5 | 2026 | 88 | 0.410 |
Why?
| | Smoking | 2 | 2012 | 1472 | 0.400 |
Why?
| | Fatty Acids | 6 | 2026 | 457 | 0.400 |
Why?
| | Myocardium | 2 | 2009 | 934 | 0.390 |
Why?
| | Hyperglycemia | 3 | 2014 | 379 | 0.390 |
Why?
| | Benzhydryl Compounds | 1 | 2013 | 81 | 0.380 |
Why?
| | Phenols | 1 | 2013 | 106 | 0.370 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 55 | 0.370 |
Why?
| | Atrial Function | 2 | 2009 | 10 | 0.370 |
Why?
| | Culture Media, Conditioned | 2 | 2022 | 112 | 0.360 |
Why?
| | Adiposity | 5 | 2024 | 532 | 0.360 |
Why?
| | Body Mass Index | 7 | 2025 | 2445 | 0.360 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 5904 | 0.360 |
Why?
| | Islets of Langerhans | 6 | 2025 | 846 | 0.350 |
Why?
| | Resistance Training | 2 | 2025 | 186 | 0.350 |
Why?
| | Homeostasis | 1 | 2016 | 642 | 0.350 |
Why?
| | Lipoprotein Lipase | 2 | 2015 | 56 | 0.350 |
Why?
| | Hyperinsulinism | 3 | 2024 | 114 | 0.350 |
Why?
| | Physical Fitness | 4 | 2004 | 207 | 0.350 |
Why?
| | Animals | 31 | 2026 | 38030 | 0.340 |
Why?
| | Glycerol | 5 | 2015 | 90 | 0.330 |
Why?
| | Incretins | 1 | 2010 | 21 | 0.320 |
Why?
| | Sex Characteristics | 5 | 2024 | 782 | 0.310 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 46 | 0.310 |
Why?
| | Sleep Deprivation | 3 | 2021 | 206 | 0.300 |
Why?
| | Pyrazines | 1 | 2010 | 94 | 0.300 |
Why?
| | Sleep | 3 | 2021 | 888 | 0.290 |
Why?
| | Physical Education and Training | 2 | 1999 | 70 | 0.290 |
Why?
| | Triazoles | 1 | 2010 | 187 | 0.290 |
Why?
| | Rats | 6 | 2024 | 5584 | 0.280 |
Why?
| | Cytosol | 2 | 2020 | 213 | 0.280 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 84 | 0.280 |
Why?
| | Insulin-Secreting Cells | 2 | 2010 | 392 | 0.280 |
Why?
| | Thinness | 2 | 2007 | 100 | 0.260 |
Why?
| | Energy Intake | 4 | 2025 | 512 | 0.250 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 264 | 0.250 |
Why?
| | Pulmonary Gas Exchange | 3 | 2007 | 116 | 0.240 |
Why?
| | Organelles | 1 | 2026 | 55 | 0.240 |
Why?
| | T-Lymphocytes | 5 | 2000 | 1996 | 0.240 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2018 | 178 | 0.230 |
Why?
| | Young Adult | 13 | 2024 | 14218 | 0.220 |
Why?
| | Palmitates | 2 | 2018 | 21 | 0.220 |
Why?
| | Polycystic Ovary Syndrome | 2 | 2019 | 187 | 0.220 |
Why?
| | Heart Rate | 1 | 2008 | 855 | 0.210 |
Why?
| | Body Weight | 2 | 2025 | 971 | 0.210 |
Why?
| | Adipose Tissue, White | 1 | 2024 | 43 | 0.200 |
Why?
| | Prostatic Neoplasms | 3 | 2020 | 978 | 0.200 |
Why?
| | Citric Acid Cycle | 2 | 2021 | 58 | 0.200 |
Why?
| | Catecholamines | 1 | 2023 | 88 | 0.200 |
Why?
| | Caloric Restriction | 1 | 2025 | 133 | 0.200 |
Why?
| | Mice, Inbred NOD | 5 | 2015 | 613 | 0.190 |
Why?
| | Circadian Clocks | 1 | 2023 | 59 | 0.190 |
Why?
| | Adiponectin | 3 | 2015 | 241 | 0.190 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2017 | 456 | 0.190 |
Why?
| | Mitochondrial Diseases | 1 | 2023 | 92 | 0.190 |
Why?
| | Isophane Insulin, Human | 1 | 2022 | 5 | 0.190 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2022 | 22 | 0.190 |
Why?
| | Ribonucleoside Diphosphate Reductase | 1 | 2022 | 6 | 0.190 |
Why?
| | Gluconeogenesis | 2 | 2018 | 81 | 0.180 |
Why?
| | Oxygen Consumption | 4 | 2016 | 718 | 0.180 |
Why?
| | Blotting, Western | 3 | 2016 | 1179 | 0.180 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2022 | 85 | 0.180 |
Why?
| | Adipokines | 1 | 2022 | 57 | 0.180 |
Why?
| | Biopsy | 3 | 2018 | 1082 | 0.180 |
Why?
| | Dinoprostone | 1 | 2022 | 180 | 0.180 |
Why?
| | Histone Deacetylases | 1 | 2023 | 207 | 0.180 |
Why?
| | Subcellular Fractions | 2 | 2021 | 73 | 0.180 |
Why?
| | Phospholipids | 4 | 2026 | 214 | 0.180 |
Why?
| | Vasodilation | 1 | 2025 | 521 | 0.180 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 218 | 0.180 |
Why?
| | Physical Conditioning, Animal | 1 | 2024 | 242 | 0.180 |
Why?
| | Interleukin-13 | 1 | 2022 | 146 | 0.170 |
Why?
| | Case-Control Studies | 5 | 2019 | 3623 | 0.170 |
Why?
| | Indoles | 1 | 2025 | 507 | 0.170 |
Why?
| | Stearoyl-CoA Desaturase | 3 | 2012 | 66 | 0.170 |
Why?
| | Interleukin-8 | 1 | 2022 | 269 | 0.170 |
Why?
| | Dietary Supplements | 1 | 2025 | 583 | 0.170 |
Why?
| | Bone Marrow | 1 | 2023 | 306 | 0.170 |
Why?
| | Exercise Test | 5 | 2015 | 630 | 0.170 |
Why?
| | Lipolysis | 2 | 2018 | 44 | 0.170 |
Why?
| | Bone Remodeling | 1 | 2021 | 71 | 0.170 |
Why?
| | Stem Cells | 1 | 2025 | 628 | 0.160 |
Why?
| | Mice | 16 | 2026 | 18329 | 0.160 |
Why?
| | Phosphorylation | 5 | 2025 | 1707 | 0.160 |
Why?
| | Diabetic Angiopathies | 3 | 2011 | 264 | 0.160 |
Why?
| | Knee | 1 | 2001 | 72 | 0.160 |
Why?
| | Immunity | 1 | 2020 | 140 | 0.150 |
Why?
| | Antigens, Surface | 1 | 2000 | 155 | 0.150 |
Why?
| | Electric Stimulation | 1 | 2001 | 276 | 0.150 |
Why?
| | Diabetic Neuropathies | 1 | 2021 | 100 | 0.150 |
Why?
| | Autophagy-Related Proteins | 2 | 2017 | 46 | 0.150 |
Why?
| | Palmitic Acid | 2 | 2010 | 40 | 0.150 |
Why?
| | Hematopoietic Stem Cells | 1 | 2023 | 435 | 0.150 |
Why?
| | Autoantigens | 2 | 2000 | 427 | 0.150 |
Why?
| | Calorimetry, Indirect | 3 | 2019 | 72 | 0.140 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 37 | 0.140 |
Why?
| | Guanosine Triphosphate | 1 | 2018 | 89 | 0.140 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2018 | 56 | 0.140 |
Why?
| | Mitochondria | 3 | 2026 | 992 | 0.140 |
Why?
| | Kinetics | 6 | 2006 | 1567 | 0.140 |
Why?
| | Pregnancy | 8 | 2025 | 7202 | 0.140 |
Why?
| | Obesity, Abdominal | 1 | 2018 | 47 | 0.140 |
Why?
| | Interleukin-6 | 1 | 2022 | 776 | 0.140 |
Why?
| | Primary Cell Culture | 1 | 2019 | 172 | 0.140 |
Why?
| | Absorptiometry, Photon | 4 | 2025 | 277 | 0.140 |
Why?
| | Basal Metabolism | 2 | 2008 | 59 | 0.130 |
Why?
| | Muscle Contraction | 1 | 2001 | 429 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2018 | 265 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2022 | 1217 | 0.130 |
Why?
| | Metabolic Syndrome | 2 | 2013 | 360 | 0.130 |
Why?
| | Diet | 4 | 2013 | 1277 | 0.130 |
Why?
| | Cell Nucleus | 1 | 2020 | 588 | 0.130 |
Why?
| | Cohort Studies | 5 | 2021 | 6013 | 0.130 |
Why?
| | Autophagy-Related Protein-1 Homolog | 1 | 2017 | 6 | 0.130 |
Why?
| | Lung Neoplasms | 2 | 2022 | 2664 | 0.130 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2018 | 122 | 0.130 |
Why?
| | Pediatric Obesity | 1 | 2024 | 638 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2025 | 652 | 0.120 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2017 | 45 | 0.120 |
Why?
| | Extracellular Vesicles | 2 | 2018 | 171 | 0.120 |
Why?
| | Biological Transport | 1 | 2017 | 424 | 0.120 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.120 |
Why?
| | Metabolomics | 3 | 2019 | 732 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1767 | 0.120 |
Why?
| | Phenotype | 1 | 2024 | 3155 | 0.120 |
Why?
| | Microtubule-Associated Proteins | 1 | 2017 | 194 | 0.110 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 96 | 0.110 |
Why?
| | Metformin | 1 | 2019 | 329 | 0.110 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2012 | 55 | 0.110 |
Why?
| | Insulinoma | 2 | 1999 | 29 | 0.110 |
Why?
| | Pain | 1 | 2001 | 789 | 0.110 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1321 | 0.110 |
Why?
| | Weight Gain | 1 | 2019 | 561 | 0.110 |
Why?
| | Amino Acids | 1 | 2019 | 519 | 0.110 |
Why?
| | Biomarkers | 4 | 2023 | 4295 | 0.110 |
Why?
| | RNA, Messenger | 4 | 2014 | 2803 | 0.110 |
Why?
| | Adolescent | 12 | 2024 | 22529 | 0.110 |
Why?
| | Cell Hypoxia | 1 | 2015 | 247 | 0.110 |
Why?
| | Circadian Rhythm | 1 | 2019 | 512 | 0.100 |
Why?
| | Algorithms | 3 | 2015 | 1845 | 0.100 |
Why?
| | Coronary Artery Disease | 2 | 2011 | 749 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 328 | 0.100 |
Why?
| | Somatostatin | 1 | 2014 | 53 | 0.100 |
Why?
| | Oxygen | 2 | 2015 | 978 | 0.100 |
Why?
| | Receptors, AMPA | 1 | 2015 | 147 | 0.100 |
Why?
| | Cytoplasmic Granules | 1 | 1994 | 60 | 0.100 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 611 | 0.100 |
Why?
| | Regression Analysis | 1 | 2016 | 1001 | 0.100 |
Why?
| | Fructose | 1 | 2014 | 132 | 0.100 |
Why?
| | Fetal Development | 1 | 2016 | 298 | 0.100 |
Why?
| | Clone Cells | 4 | 2000 | 263 | 0.100 |
Why?
| | Neurodegenerative Diseases | 1 | 2015 | 142 | 0.100 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1189 | 0.100 |
Why?
| | Mice, Inbred C57BL | 3 | 2026 | 5983 | 0.100 |
Why?
| | Leg | 3 | 1999 | 242 | 0.100 |
Why?
| | Glycogen | 2 | 2025 | 55 | 0.090 |
Why?
| | Antigens, Neoplasm | 2 | 1994 | 271 | 0.090 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2012 | 33 | 0.090 |
Why?
| | Macaca | 3 | 2018 | 66 | 0.090 |
Why?
| | Taxoids | 1 | 2012 | 114 | 0.090 |
Why?
| | Progestins | 1 | 2012 | 66 | 0.090 |
Why?
| | Coronary Vessels | 2 | 2010 | 246 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2597 | 0.090 |
Why?
| | Cholesterol | 2 | 2013 | 408 | 0.090 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2013 | 139 | 0.090 |
Why?
| | Signal Transduction | 5 | 2025 | 5216 | 0.090 |
Why?
| | Myocardial Contraction | 1 | 2013 | 293 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2025 | 440 | 0.080 |
Why?
| | Hemodynamics | 3 | 2008 | 1118 | 0.080 |
Why?
| | Reference Values | 2 | 2010 | 798 | 0.080 |
Why?
| | Fenofibrate | 1 | 2011 | 28 | 0.080 |
Why?
| | Recovery of Function | 1 | 2015 | 716 | 0.080 |
Why?
| | Hypoxia | 1 | 2018 | 1199 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 977 | 0.080 |
Why?
| | Sitagliptin Phosphate | 1 | 2010 | 31 | 0.080 |
Why?
| | Child | 9 | 2024 | 22707 | 0.080 |
Why?
| | Estradiol | 2 | 2019 | 515 | 0.080 |
Why?
| | Hypolipidemic Agents | 1 | 2011 | 89 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 2121 | 0.080 |
Why?
| | Cell Line | 5 | 2022 | 2823 | 0.080 |
Why?
| | Nicotine | 1 | 2012 | 331 | 0.080 |
Why?
| | Retinoid X Receptor gamma | 1 | 2009 | 4 | 0.080 |
Why?
| | Metabolic Clearance Rate | 2 | 2006 | 115 | 0.070 |
Why?
| | PPAR alpha | 1 | 2009 | 55 | 0.070 |
Why?
| | C-Peptide | 1 | 2010 | 190 | 0.070 |
Why?
| | Expiratory Reserve Volume | 1 | 2008 | 1 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 454 | 0.070 |
Why?
| | Bicycling | 1 | 2010 | 117 | 0.070 |
Why?
| | Lipoproteins | 1 | 2010 | 166 | 0.070 |
Why?
| | Calcinosis | 1 | 2011 | 234 | 0.070 |
Why?
| | Gene Expression | 3 | 2023 | 1476 | 0.070 |
Why?
| | Proteins | 3 | 2015 | 1023 | 0.070 |
Why?
| | Coronary Circulation | 1 | 2008 | 134 | 0.070 |
Why?
| | Ethinyl Estradiol | 1 | 1988 | 16 | 0.070 |
Why?
| | Arteries | 2 | 2000 | 261 | 0.070 |
Why?
| | Calcium | 2 | 2010 | 1190 | 0.070 |
Why?
| | Receptor, Insulin | 1 | 2007 | 93 | 0.060 |
Why?
| | Regional Blood Flow | 2 | 1999 | 514 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2012 | 881 | 0.060 |
Why?
| | Lipid Droplets | 1 | 2026 | 21 | 0.060 |
Why?
| | Pancreatic Neoplasms | 2 | 1999 | 928 | 0.060 |
Why?
| | Hyperphagia | 1 | 2006 | 38 | 0.060 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4560 | 0.060 |
Why?
| | Cardiovascular Diseases | 3 | 2018 | 2187 | 0.060 |
Why?
| | Indoleacetic Acids | 1 | 2025 | 10 | 0.060 |
Why?
| | Hepatic Stellate Cells | 1 | 2025 | 14 | 0.060 |
Why?
| | Adaptation, Physiological | 1 | 2010 | 560 | 0.060 |
Why?
| | Overweight | 1 | 2011 | 614 | 0.060 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2025 | 27 | 0.060 |
Why?
| | Heart | 1 | 2009 | 626 | 0.060 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1988 | 185 | 0.060 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2025 | 60 | 0.060 |
Why?
| | GTPase-Activating Proteins | 1 | 2025 | 81 | 0.060 |
Why?
| | Sex Factors | 4 | 2018 | 2105 | 0.060 |
Why?
| | Infant | 3 | 2024 | 10077 | 0.050 |
Why?
| | Sex Hormone-Binding Globulin | 2 | 2019 | 52 | 0.050 |
Why?
| | Glucose-6-Phosphatase | 2 | 2001 | 32 | 0.050 |
Why?
| | ARNTL Transcription Factors | 1 | 2023 | 17 | 0.050 |
Why?
| | Maternal Exposure | 1 | 2025 | 189 | 0.050 |
Why?
| | Pyruvic Acid | 1 | 2004 | 51 | 0.050 |
Why?
| | Uncoupling Protein 1 | 1 | 2023 | 17 | 0.050 |
Why?
| | Adipogenesis | 1 | 2024 | 56 | 0.050 |
Why?
| | Ubiquinone | 1 | 2023 | 35 | 0.050 |
Why?
| | Electron Transport | 1 | 2023 | 110 | 0.050 |
Why?
| | Metabolome | 2 | 2019 | 388 | 0.050 |
Why?
| | Cardiorespiratory Fitness | 1 | 2024 | 74 | 0.050 |
Why?
| | Thermogenesis | 1 | 2023 | 45 | 0.050 |
Why?
| | Carbohydrate Metabolism | 2 | 2004 | 59 | 0.050 |
Why?
| | Adipose Tissue, Brown | 1 | 2023 | 60 | 0.050 |
Why?
| | Physical Exertion | 1 | 2004 | 205 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 192 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2022 | 47 | 0.050 |
Why?
| | Aged | 6 | 2018 | 26153 | 0.050 |
Why?
| | Primates | 1 | 2023 | 133 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2930 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2023 | 266 | 0.040 |
Why?
| | Prognosis | 2 | 2023 | 4316 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 7123 | 0.040 |
Why?
| | Protein Binding | 2 | 2018 | 2238 | 0.040 |
Why?
| | Osteocalcin | 1 | 2021 | 38 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2006 | 2188 | 0.040 |
Why?
| | Swine, Miniature | 2 | 2013 | 89 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2015 | 199 | 0.040 |
Why?
| | Acute Disease | 1 | 2024 | 1036 | 0.040 |
Why?
| | Neoplasms | 1 | 2017 | 2906 | 0.040 |
Why?
| | Muscle Strength | 1 | 2024 | 332 | 0.040 |
Why?
| | Ranolazine | 1 | 2020 | 23 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 2214 | 0.040 |
Why?
| | Torque | 1 | 2001 | 82 | 0.040 |
Why?
| | Oxidative Stress | 2 | 2018 | 1356 | 0.040 |
Why?
| | Electrodes | 1 | 2001 | 111 | 0.040 |
Why?
| | Collagen Type I | 1 | 2021 | 143 | 0.040 |
Why?
| | Adenocarcinoma | 1 | 1988 | 925 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2022 | 212 | 0.040 |
Why?
| | Testosterone | 2 | 2019 | 416 | 0.040 |
Why?
| | Detergents | 1 | 2000 | 43 | 0.040 |
Why?
| | Chromatography, Ion Exchange | 1 | 2000 | 57 | 0.040 |
Why?
| | Chromatography, Gel | 1 | 2000 | 130 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2020 | 224 | 0.040 |
Why?
| | Serine | 1 | 2021 | 143 | 0.040 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2000 | 112 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 331 | 0.040 |
Why?
| | Solubility | 1 | 2000 | 240 | 0.040 |
Why?
| | Cell Membrane | 2 | 2000 | 707 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 325 | 0.040 |
Why?
| | Mice, SCID | 1 | 2000 | 369 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2000 | 174 | 0.040 |
Why?
| | Eating | 1 | 2021 | 387 | 0.040 |
Why?
| | Isometric Contraction | 1 | 2001 | 190 | 0.040 |
Why?
| | Glucose Transporter Type 4 | 1 | 2018 | 39 | 0.040 |
Why?
| | Osmolar Concentration | 1 | 1999 | 168 | 0.040 |
Why?
| | Thromboplastin | 1 | 2018 | 67 | 0.040 |
Why?
| | Swine | 2 | 2013 | 825 | 0.040 |
Why?
| | Glucagon | 1 | 1999 | 114 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2024 | 2524 | 0.030 |
Why?
| | Muscle Proteins | 1 | 2000 | 242 | 0.030 |
Why?
| | Postprandial Period | 1 | 1999 | 114 | 0.030 |
Why?
| | Pilot Projects | 1 | 2023 | 1891 | 0.030 |
Why?
| | Perception | 1 | 2001 | 378 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2025 | 4148 | 0.030 |
Why?
| | Research Design | 1 | 2024 | 1137 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 439 | 0.030 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 767 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2020 | 499 | 0.030 |
Why?
| | Carbon Dioxide | 1 | 1999 | 227 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2023 | 835 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 365 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 767 | 0.030 |
Why?
| | Cell Proliferation | 2 | 2015 | 2507 | 0.030 |
Why?
| | Nutritional Status | 1 | 1999 | 353 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 3542 | 0.030 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 118 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2000 | 728 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 981 | 0.030 |
Why?
| | Waist Circumference | 1 | 2015 | 143 | 0.030 |
Why?
| | Deuterium | 1 | 2015 | 100 | 0.030 |
Why?
| | HeLa Cells | 1 | 2017 | 632 | 0.030 |
Why?
| | Androgens | 1 | 2016 | 181 | 0.030 |
Why?
| | Lymphocyte Activation | 3 | 1994 | 1132 | 0.030 |
Why?
| | Epitopes | 1 | 1997 | 473 | 0.030 |
Why?
| | Prospective Studies | 2 | 2018 | 8057 | 0.030 |
Why?
| | Protein Subunits | 1 | 2015 | 229 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 919 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 2062 | 0.030 |
Why?
| | Autophagy | 1 | 2017 | 291 | 0.030 |
Why?
| | Centrifugation, Density Gradient | 1 | 1994 | 36 | 0.030 |
Why?
| | Culture Techniques | 1 | 1994 | 66 | 0.030 |
Why?
| | Cell Fractionation | 1 | 1994 | 50 | 0.030 |
Why?
| | Animal Feed | 1 | 2014 | 48 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 506 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 2090 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2000 | 1164 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1997 | 409 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 1994 | 396 | 0.020 |
Why?
| | Acyl Coenzyme A | 1 | 2013 | 32 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2014 | 181 | 0.020 |
Why?
| | Memory | 1 | 2015 | 295 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2013 | 59 | 0.020 |
Why?
| | Amyloid beta-Peptides | 1 | 2015 | 244 | 0.020 |
Why?
| | Gonanes | 1 | 2012 | 23 | 0.020 |
Why?
| | Risk Factors | 3 | 2012 | 10885 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2024 | 6447 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2865 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2015 | 558 | 0.020 |
Why?
| | Cardiolipins | 1 | 2013 | 82 | 0.020 |
Why?
| | Anaerobic Threshold | 2 | 2004 | 28 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 1994 | 886 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 1992 | 159 | 0.020 |
Why?
| | Amino Acid Sequence | 3 | 2001 | 2129 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2015 | 519 | 0.020 |
Why?
| | Fetus | 1 | 2016 | 804 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 2015 | 473 | 0.020 |
Why?
| | Molecular Weight | 1 | 2012 | 312 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2923 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 51 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 2001 | 2883 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 671 | 0.020 |
Why?
| | Learning | 1 | 2015 | 443 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2015 | 541 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2013 | 307 | 0.020 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 243 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1852 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2011 | 201 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2010 | 2769 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 387 | 0.020 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.020 |
Why?
| | Hippocampus | 1 | 2015 | 971 | 0.020 |
Why?
| | Conserved Sequence | 2 | 2001 | 244 | 0.020 |
Why?
| | Sequence Alignment | 2 | 2001 | 362 | 0.020 |
Why?
| | Child, Preschool | 1 | 2024 | 11853 | 0.020 |
Why?
| | Cloning, Molecular | 2 | 2001 | 538 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 527 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5423 | 0.020 |
Why?
| | Spleen | 1 | 2010 | 508 | 0.020 |
Why?
| | Leydig Cells | 1 | 1988 | 15 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2440 | 0.020 |
Why?
| | Gonadotropins, Pituitary | 1 | 1988 | 22 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 3124 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 450 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2010 | 346 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 382 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 1992 | 870 | 0.020 |
Why?
| | Base Sequence | 2 | 2001 | 2170 | 0.020 |
Why?
| | Macrophages | 1 | 2014 | 1507 | 0.010 |
Why?
| | Cytokines | 1 | 2014 | 2067 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3904 | 0.010 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 443 | 0.010 |
Why?
| | Patient Selection | 1 | 2010 | 738 | 0.010 |
Why?
| | Age Factors | 1 | 2012 | 3342 | 0.010 |
Why?
| | Femoral Vein | 1 | 2004 | 38 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2004 | 124 | 0.010 |
Why?
| | Hormones | 1 | 2004 | 135 | 0.010 |
Why?
| | Alanine | 1 | 2004 | 169 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1779 | 0.010 |
Why?
| | Femoral Artery | 1 | 2004 | 190 | 0.010 |
Why?
| | Inflammation | 1 | 2014 | 2878 | 0.010 |
Why?
| | Glycolysis | 1 | 2004 | 340 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2010 | 1097 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2001 | 200 | 0.010 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2000 | 21 | 0.010 |
Why?
| | Catalytic Domain | 1 | 2001 | 234 | 0.010 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 75 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2382 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 294 | 0.010 |
Why?
| | Mice, Obese | 1 | 1999 | 68 | 0.010 |
Why?
| | Myosin Heavy Chains | 1 | 2000 | 183 | 0.010 |
Why?
| | Fishes | 1 | 1999 | 109 | 0.010 |
Why?
| | Open Reading Frames | 1 | 1999 | 130 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1999 | 387 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 1999 | 371 | 0.010 |
Why?
| | Exons | 1 | 1999 | 363 | 0.010 |
Why?
| | Dogs | 1 | 1999 | 458 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1999 | 247 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2001 | 1246 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1999 | 1261 | 0.010 |
Why?
| | Genetic Variation | 1 | 1999 | 972 | 0.010 |
Why?
| | Models, Molecular | 1 | 1999 | 1598 | 0.010 |
Why?
| | Trinitrobenzenes | 1 | 1992 | 14 | 0.010 |
Why?
| | Adenoma, Islet Cell | 1 | 1992 | 6 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1992 | 49 | 0.010 |
Why?
| | Haptens | 1 | 1992 | 25 | 0.010 |
Why?
| | Ovalbumin | 1 | 1992 | 194 | 0.010 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 1992 | 130 | 0.010 |
Why?
| | Interleukin-2 | 1 | 1992 | 440 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 1989 | 302 | 0.000 |
Why?
| | Pituitary Gland | 1 | 1989 | 149 | 0.000 |
Why?
| | Islets of Langerhans Transplantation | 1 | 1989 | 70 | 0.000 |
Why?
|
|
Bergman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|